Service utilisation outcomes: hospital admission or days in hospital · patients with schizophrenia
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · patients with schizophrenia
1 finding from 1 review
Disease control (healing of skin lesions) at day 21 · bullous pemphigoid
Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in disease control (healing of skin lesions) at day 21.… compared with standard clobetasol propionate cream regimen (40 g/day) (moderate certainty).
1 finding from 1 review
Total effective rate at 4 days · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Rofecoxib (oral, 50 mg on first day then 25 to 50 mg per day for 4… showed no clear difference in total effective rate at 4 days compared with tinidazole (1 g per day for 3 days); GRADE not reported.
1 finding from 1 review
Clinical severity score (post‐treatment) at day 3 · infants up to 24 months of age with acute bronchiolitis
1 finding from 1 review
Death at day 30Â · AKI
Early showed no clear difference in death at day 30Â compared with standard initiation of kidney replacement therapy (KRT) (low certainty).
1 finding from 1 review
Confirmed SARS‐CoV‐2 infection · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Bamlanivimab probably leads to lower infection with SARS‐CoV‐2 by day 30 compared with placebo (moderate certainty).
1 finding from 1 review
Confirmed SARS‐CoV‐2 infection · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab leads to lower infection with SARS‐CoV‐2 by day 30 compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review
Hospital re‐admission within 30 days of discharge · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab showed no clear difference in admission to hospital by day 30 compared with placebo (low certainty).
1 finding from 1 review
Sore throat · patients with sore throat
Antibiotics probably leads to lower sore throat: day 3 compared with control (moderate certainty).
1 finding from 1 review
Fever · patients with sore throat
Antibiotics showed no clear difference in fever: day 3 compared with control (high certainty).
1 finding from 1 review
Headache · patients with sore throat
Antibiotics leads to lower headache: day 3 compared with control (high certainty).
1 finding from 1 review
Oxygen efficiency (PaO2/FiO2) day 3 postoperative · patients with ALI and ARDS
1 finding from 1 review
Global assessment of treatment success · acute gout
NSAIDs showed no clear difference in patients' global assessment of treatment success at day 3 to 4 compared with glucocorticoids (moderate certainty).
1 finding from 1 review
RR 0.92 [0.7, 1.22]
Studies not reported
Moderate
Severity of pain on day 3 · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes severity of pain on day 3 compared with standard treatment alone (very low certainty).
1 finding from 1 review
Mortality by day 30 · non‐hospitalised individuals with COVID‐19
1 finding from 1 review
Quality of life by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab showed no clear difference in mortality by day 30 compared with placebo (low certainty).
1 finding from 1 review